The use of atypical antipsychotics in pediatric bipolar disorder

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 4, 2008, Pages 4-8

  Chang, Kiki D ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

AGITATION; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MANIA; MENTAL DISEASE; MIXED MANIA AND DEPRESSION; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; WEIGHT GAIN; ADOLESCENT; ATTENTION DEFICIT DISORDER; CHEMICALLY INDUCED DISORDER; CHILD; COMORBIDITY; DRUG EFFECT; OBESITY;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BIPOLAR DISORDER; CHILD; COMORBIDITY; DIBENZOTHIAZEPINES; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; OBESITY; PIPERAZINES; QUINOLONES; RISPERIDONE; THIAZOLES; WEIGHT GAIN;

EID: 46649116784     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Post RM, Kowatch RA. The health care crisis of childhood-onset bipolar illness: some recommendations for its amelioration. J Clin Psychiatry 2006;67:115-125
2. Leverich GS, Post RM, Keck PE Jr, et al. The poor prognosis of childhood-onset bipolar disorder. J Pediatr 2007;150:485-490
3. Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2004;55:875-881
4. Moreno C, Laje G, Blanco C, et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007;64:1032-1039
5. McClellan J, Kowatch R, Findling RL, et al. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007;46:107-125. Correction 2007;46:786 Available at http://www.aacap.org/galleries/Practice Parameters/ JAACAP_Bipolar_2007.pdf. Accessed Dec 17, 2007
6. McClellan J. Commentary: treatment guidelines for child and adolescent bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:236-239
7. National Institute of Mental Health. Director's Update: NIMH perspective on diagnosing and treating bipolar disorder in children. 2007. Available at www.nimh.nih.gov/about/director/updates/2007/nimh-perspective-on-diagnosing-and- treating-bipolar-disorder-in-children. Accessed Jan 9, 2008
8. Lin PI, McInnis MG, Potash JB, et al. Clinical correlates and familial aggregation of age at onset in bipolar disorder. Am J Psychiatry 2006;163:240-246
9. Carter TD, Mundo E, Parikh SV. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res 2003;37:297-303
10. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:213-235
11. Madaan V, Chang KD. Pharmacotherapeutic strategies for pediatric bipolar disorder. Expert Opin Pharmacother 2007;8:1801-1819
12. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;164:1547-1556
13. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-435
14. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine in the treatment of adolescents with bipolar mania; 26-week open-label extension [poster]. Presented at the 47th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU); June 13, 2007; Boca Raton, Fla
15. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69(suppl 4):26-36
16. Biederman J, Mick E, Hammerness P, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in pre-school-age children. Biol Psychiatry 2005;58:589-594
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
18. Risperdal [package insert]. Titusville, NJ: Janssen, LP; 2007. Available at http://www.risperdal.com/risperdal/shared/pi/risperdal.pdf. Accessed Dec 14, 2007
19. Biederman J, Mick E, Wozniak J, et al. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005;15:311-317
20. Pandina G, DelBello MP, Kushner S, et al. Risperidone for the treatment of acute mania in bipolar youth [poster]. Presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); Oct 23-28 2007; Boston, Mass
21. DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006;45:305-313
22. DelBello MP, Findling RL, Earley WR, et al. Efficacy of quetiapine in children and adolescents with bipolar mania [poster]. Presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); Oct 23-28, 2007; Boston, Mass
23. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-1223
24. Versavel M, DelBello MP, Ice K, et al. Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia or schizoaffective disorder [abstract]. Neuropsychopharmacology 2005;30(suppl 1):S122-S123
25. Chang KD, Nyilas M, Aurang C, et al. Efficacy of aripiprazole in children (10-17 years old) with mania [poster]. Presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); Oct 23-28, 2007; Boston, Mass
26. Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006;63:1139-1148
27. Baumer FM, Howe M, Gallelli K, et al. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol Psychiatry 2006;60:1005-1012
28. Duffy A, Alda M, Crawford L, et al. The early manifestations of bipolar disorder: a longitudinal prospective study of the offspring of bipolar parents. Bipolar Disord 2007;9:828-838
29. DelBello MP, Adler CM, Whitsel RM, et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 2007;68:789-795